Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Dianthus Therapeutics, Inc. - Common Stock (NQ:DNTH)

41.65 -0.48 (-1.14%)
Streaming Delayed Price Updated: 12:06 PM EST, Dec 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Dianthus Therapeutics, Inc. - Common Stock

< Previous 1 2 3 Next >
News headline image
Worthington Steel Posts Upbeat Results, Joins Summit Midstream Partners, FedEx And Other Big Stocks Moving Higher On Friday ↗
U.S. stocks were mixed, with the Dow Jones index falling around 50 points on Friday. 
Via Benzinga
Topics Stocks
News headline image
DNTH Stock Earnings: Dianthus Therapeutics Beats EPS, Beats Revenue for Q4 2023 ↗
DNTH stock results show that Dianthus Therapeutics beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023. 
Via InvestorPlace
News headline image
Dianthus Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dianthus Therapeutics Announces Initiation of Phase 2 MaGic Trial of DNTH103 In Generalized Myasthenia Gravis (gMG)
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Decoding 4 Analyst Evaluations For Dianthus Therapeutics ↗
 
Via Benzinga
News headline image
Why Dianthus Therapeutics (DNTH) Stock Is Exploding Higher ↗
Dianthus Therapeutics shares traded higher by 37% Monday. The company announced a $230 million private placement. 
Via Benzinga
News headline image
DNTH Stock Earnings: Dianthus Therapeutics Reported Results for Q3 2023 ↗
Dianthus Therapeutics just reported results for the third quarter of 2023. 
Via InvestorPlace
News headline image
Antibody Player Dianthus Therapeutics Has Potential Amid Active M&A Landscape in Complement-Focused Firms: Analyst ↗
Wedbush initiated coverage on Dianthus Therapeutics Inc (NASDAQ: DNTH), noting its lead program DNTH103 as a well-positioned monoclonal antibody directed against the active form of the  
Via Benzinga
News headline image
Dianthus' Monoclonal Antibody On Promising Pathway To Gaining The Upper Hand - Analyst ↗
Raymond James initiated coverage on Dianthus Therapeutics Inc (NASDAQ: DNTH), a recent reverse merger with the old Magenta Therapeutics. 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For September 28, 2023 ↗
 
Via Benzinga
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.